PL406631A1 - Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie - Google Patents

Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie

Info

Publication number
PL406631A1
PL406631A1 PL406631A PL40663113A PL406631A1 PL 406631 A1 PL406631 A1 PL 406631A1 PL 406631 A PL406631 A PL 406631A PL 40663113 A PL40663113 A PL 40663113A PL 406631 A1 PL406631 A1 PL 406631A1
Authority
PL
Poland
Prior art keywords
antigen
vaccine
production
influenza vaccine
producing
Prior art date
Application number
PL406631A
Other languages
English (en)
Other versions
PL238555B1 (pl
Inventor
Edyta Kopera
Krystyna Maria Grzelak
Włodzimierz Wiktor Zagórski-Ostoja
Bogusław Szewczyk
Violetta Sączyńska
Katarzyna Florys
Violetta Cecuda-Adamczewska
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Instytut Biotechnologii i Antybiotyków
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk, Instytut Biotechnologii i Antybiotyków filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL406631A priority Critical patent/PL238555B1/pl
Priority to EP14830896.8A priority patent/EP3083660B1/en
Priority to PCT/PL2014/000148 priority patent/WO2015093996A1/en
Priority to PL14830896.8T priority patent/PL3083660T3/pl
Publication of PL406631A1 publication Critical patent/PL406631A1/pl
Publication of PL238555B1 publication Critical patent/PL238555B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Ujawniono antygen, szczepionkę przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu do wytwarzania szczepionki przeciwko grypie. Wynalazek dotyczy nowego sposobu wytwarzania antygenu szczepionkowego oraz nowego antygenu. Proponowane rozwiązanie prowadzi do uzyskania wysoko immunogennego antygenu co nie wymaga kontaktu z wirusem, a jedynie z genem hemaglutyniny. Szczepionka przeciw grypie nie zawiera wirusa ani jego fragmentów, nie zawiera komórek innych organizmów ani ich fragmentów, a jedynie oczyszczony antygen.
PL406631A 2013-12-20 2013-12-20 Sposób wytwarzania hydrofilowej domeny hemaglutyniny wirusa H5 PL238555B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL406631A PL238555B1 (pl) 2013-12-20 2013-12-20 Sposób wytwarzania hydrofilowej domeny hemaglutyniny wirusa H5
EP14830896.8A EP3083660B1 (en) 2013-12-20 2014-12-19 Method of influenza antigen production
PCT/PL2014/000148 WO2015093996A1 (en) 2013-12-20 2014-12-19 Antigen, influenza vaccine, system for vaccine manufacturing, method of antigen production, and use of antigen to produce an influenza vaccine
PL14830896.8T PL3083660T3 (pl) 2013-12-20 2014-12-19 Sposób wytwarzania antygenu przeciwko grypie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL406631A PL238555B1 (pl) 2013-12-20 2013-12-20 Sposób wytwarzania hydrofilowej domeny hemaglutyniny wirusa H5

Publications (2)

Publication Number Publication Date
PL406631A1 true PL406631A1 (pl) 2015-06-22
PL238555B1 PL238555B1 (pl) 2021-09-06

Family

ID=52424083

Family Applications (2)

Application Number Title Priority Date Filing Date
PL406631A PL238555B1 (pl) 2013-12-20 2013-12-20 Sposób wytwarzania hydrofilowej domeny hemaglutyniny wirusa H5
PL14830896.8T PL3083660T3 (pl) 2013-12-20 2014-12-19 Sposób wytwarzania antygenu przeciwko grypie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14830896.8T PL3083660T3 (pl) 2013-12-20 2014-12-19 Sposób wytwarzania antygenu przeciwko grypie

Country Status (3)

Country Link
EP (1) EP3083660B1 (pl)
PL (2) PL238555B1 (pl)
WO (1) WO2015093996A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL235555B1 (pl) * 2014-06-24 2020-09-07 Inst Biotechnologii I Antybiotykow Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu
PL422982A1 (pl) * 2017-09-26 2019-04-08 Instytut Biochemii I Biofizyki Polskiej Akademii Nauk Antygen uniwersalny, uniwersalna szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu i zastosowanie antygenu do wytwarzania szczepionki uniwersalnej przeciwko grypie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101605558A (zh) * 2005-08-16 2009-12-16 夏威夷生物技术公司 流感重组亚单位疫苗
US20070286873A1 (en) * 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
EP2595653B1 (en) * 2010-07-23 2017-06-28 Novavax AB Influenza vaccine
PL220281B1 (pl) * 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA

Also Published As

Publication number Publication date
WO2015093996A1 (en) 2015-06-25
EP3083660A1 (en) 2016-10-26
PL238555B1 (pl) 2021-09-06
PL3083660T3 (pl) 2021-02-22
EP3083660B1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
BR112018008102A2 (pt) vacina de vírus sincicial respiratório
MX386793B (es) Vacunas individualizadas para el cancer.
EP4349404A3 (en) Respiratory virus vaccines
MX2020009401A (es) Ligadores de nucleótidos modificados.
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
EA201300915A1 (ru) Новый европейский штамм prrsv
MX2014015287A (es) Derivado del ester del acido heteroarilcarboxilico.
PH12013502442A1 (en) Inactivated dengue virus vaccine
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
MX2015015188A (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
MX377149B (es) Microorganismo recombinante para la produccion mejorada de productos quimicos finos.
MX387421B (es) Producción de virus en huevos aviares.
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
MX382530B (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
MX363149B (es) Vacunas de nucleoproteina de la influenza.
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
MX2015009330A (es) Reordenamiento del virus de influenza.
MX381745B (es) Vacunas de pestivirus para temblores congenitos.
MX2019007924A (es) Vacunas contra la influenza.
UY34840A (es) Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos
BR112015007678A2 (pt) vacina para cooperia